About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker VSTM · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
NCT07659782 · Non-Small Cell Lung Cancer
VS-7375
VSTM
Verastem, Inc.
Phase 2Recruiting105Jun 2027Registry ↗
Nov 13, 2026A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
NCT07644559 · Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
VS-7375, cetuximab (or panitumumab if α-gal IgE+ or cetuxim…
VSTM
Verastem, Inc.
Phase 2Recruiting185Jun 2027Registry ↗
Nov 12, 2026A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
NCT07659795 · Colorectal Cancer
VS-7375, cetuximab
VSTM
Verastem, Inc.
Phase 2Recruiting150Jun 2027Registry ↗
Nov 10, 2026A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221 · Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer
VS-7375, Cetuximab
VSTM
Verastem, Inc.
Phase 1/2Recruiting616Dec 2028Registry ↗
Nov 2, 2026A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Canc…
NCT06072781 · Low Grade Serous Ovarian Cancer
avutometinib, Defactinib
VSTM
Verastem, Inc.
Phase 3Recruiting270Oct 15, 2028Registry ↗
Aug 5, 2026Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grad…
NCT07747506 · Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
avutometinib + defactininb combination
VSTM
Verastem, Inc.
Phase 2Not yet recruiting2Aug 1, 2027Registry ↗
Jul 2, 2026Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
NCT05375994 · Non Small Cell Lung Cancer, KRAS Activating Mutation
avutometinib (VS-6766) and adagrasib
VSTM
Verastem, Inc.
Phase 1/2Completed12Jun 15, 2026Registry ↗
Jan 12, 2026Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC…
NCT05074810 · Non Small Cell Lung Cancer, KRAS Activating Mutation
avutometinib and sotorasib, avutometinib and sotorasib and…
VSTM
Verastem, Inc.
Phase 1/2Active, not recruiting153Jun 2026Registry ↗
Dec 17, 2025A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patie…
NCT06682572 · Low Grade Serous Ovarian Cancer, Ovarian Cancer
Avutometinib (VS-6766) + Defactinib (VS-6063)
VSTM
Verastem, Inc.
Phase 2Active, not recruiting16Dec 2025Registry ↗
Sep 2, 2025Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pa…
NCT05669482 · KRAS Activating Mutation, Metastatic Cancer
avutometinib (VS-6766) and defactinib in combination with g…
VSTM
Verastem, Inc.
Phase 1/2Active, not recruiting40Aug 31, 2026Registry ↗
Jan 29, 2025A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Ser…
NCT04625270 · Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
avutometinib (VS-6766), avutometinib (VS-6766) and defactin…
VSTM
Verastem, Inc.
Phase 2Active, not recruiting225Nov 15, 2024Registry ↗
Feb 20, 2024Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesoth…
NCT02004028 · Malignant Pleural Mesothelioma
VS-6063
VSTM
Verastem, Inc.
Phase 2Terminated35Jun 19, 2019Registry ↗
Jan 12, 2024A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Smal…
NCT04620330 · Non Small Cell Lung Cancer, KRAS Activating Mutation
avutometinib (VS-6766), avutometinib (VS-6766) and Defactin…
VSTM
Verastem, Inc.
Phase 2Completed90Aug 29, 2023Registry ↗
May 10, 2022Food Effect of VS-6766 in Healthy Adult Subjects
NCT05187169 · Food Effect
VS-6766
VSTM
Verastem, Inc.
Phase 1Completed18Apr 12, 2022Registry ↗
Apr 30, 2019Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activi…
NCT02943317 · Epithelial Ovarian Cancer
Part A - VS-6063, Part A - Avelumab
VSTM
Verastem, Inc.
Phase 1Terminated98Aug 28, 2018Registry ↗
Jul 28, 2017Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies
NCT01849744 · Non Hematologic Cancers, Metastatic Cancer
VS-4718
VSTM
Verastem, Inc.
Phase 1Terminated48Apr 2017Registry ↗
Jul 27, 2017Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advan…
NCT02651727 · Pancreatic Cancer
Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine, Par…
VSTM
Verastem, Inc.
Phase 1Terminated13Jan 2017Registry ↗
May 17, 2017Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer
NCT01778803 · Ovarian Cancer
defactinib, Paclitaxel
VSTM
Verastem, Inc.
Phase 1Completed22Feb 23, 2015Registry ↗
Apr 13, 2017Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer
NCT01951690 · Non Small Cell Lung Cancer, Lung Cancer
defactinib (VS-6063)
VSTM
Verastem, Inc.
Phase 2Completed55Jun 2016Registry ↗
Mar 9, 2017Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies
NCT01943292 · Non Hematologic Cancers
Defactinib
VSTM
Verastem, Inc.
Phase 1Completed9Jun 9, 2014Registry ↗
Jan 30, 2017A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Hea…
NCT02913716 · Healthy Subjects
defactinib
VSTM
Verastem, Inc.
Phase 1Completed5Sep 2015Registry ↗
Jan 30, 2017A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects Wi…
NCT02372227 · Relapsed Malignant Mesothelioma
VS-5584 and VS-6063
VSTM
Verastem, Inc.
Phase 1Terminated21Oct 2015Registry ↗
Jan 30, 2017Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
NCT01870609 · Malignant Pleural Mesothelioma
defactinib (VS-6063), Placebo
VSTM
Verastem, Inc.
Phase 2Terminated344Jan 2016Registry ↗
Jan 27, 2017Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia
NCT02215629 · Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or…
VS-4718
VSTM
Verastem, Inc.
Phase 1Withdrawn0Sep 2016Registry ↗
Jan 27, 2017Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or…
NCT01991938 · Non Hematologic Cancers, Metastatic Cancer
VS-5584
VSTM
Verastem, Inc.
Phase 1Terminated75Dec 2016Registry ↗
Jan 25, 2017A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies
NCT00787033 · Cancer
PF-04554878
VSTM
Verastem, Inc.
Phase 1Completed46Mar 2011Registry ↗

26 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:11 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances